SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-21-090198
Filing Date
2021-07-08
Accepted
2021-07-08 16:01:34
Documents
12
Period of Report
2021-07-01
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2121667d1_8k.htm   iXBRL 8-K 24881
  Complete submission text file 0001104659-21-090198.txt   197823

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA srne-20210701.xsd EX-101.SCH 3224
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE srne-20210701_lab.xml EX-101.LAB 34593
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE srne-20210701_pre.xml EX-101.PRE 22736
5 EXTRACTED XBRL INSTANCE DOCUMENT tm2121667d1_8k_htm.xml XML 3490
Mailing Address 4955 DIRECTORS PLACE SAN DIEGO CA 92121
Business Address 4955 DIRECTORS PLACE SAN DIEGO CA 92121 858-203-4100
Sorrento Therapeutics, Inc. (Filer) CIK: 0000850261 (see all company filings)

IRS No.: 330344842 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36150 | Film No.: 211080191
SIC: 2836 Biological Products, (No Diagnostic Substances)